Global Nucleic Acid Isolation and Purification Market Segmentation, By Product (Instruments, Kits, and Reagents), Method (Magnetic Bead-Based Isolation and Purification, Column -Based Isolation and Purification, Reagent-Based Isolation and Purification, and Others), Type (Next Generation Sequencing (NGS), Genomic DNA Isolation and Purification, Total RNA Isolation and Purification, PCR Clean-Up, Plasmid DNA Isolation and Purification, Messenger RNA Isolation and Purification, Circulating Nucleic Acid Isolation and Purification, MicroRNA Isolation and Purification, and Others), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture and Animal Research, and Others), Sample Type (FFPE Samples, Blood Cells, Bacteria, Yeast, and Plants, Cell-Free Samples, Cultured Cells, Mammalian Cells, Brain and Kidney Tissue, and Others), End User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Contract Development and manufacturing Organization (CDMO), Academic/Research Institutes, and Others) - Industry Trends and Forecast to 2032
Nucleic Acid Isolation and Purification Market Analysis
The global nucleic acid isolation and purification market is witnessing significant growth, driven by increasing prevalence of genetic disorders, increasing demand for diagnostic testing, rising investment in genomics research and increase in launch of diagnostic products. The market is characterized by the presence of key players, ongoing research and development, and strategic collaborations. The North American region dominates the market, followed by Europe and the Asia-Pacific. The market's expansion is also supported by favorable regulatory environments and increasing healthcare expenditure.
North America holds the largest share of the market, attributed to its advanced healthcare infrastructure, substantial investment in research and development, and high innovation levels. Europe follows closely, with a strong market presence driven by similar factors. The Asia-Pacific region is expected to witness the fastest growth rate due to rapid advancements in healthcare infrastructure and increased investments in research and development across the region. Also, increasing prevalence of genetic disorders, increasing demand for diagnostic testing, rising investment in genomics research and increase in launch of diagnostic products are driving the adoption of global nucleic acid isolation and purification market.
Global Nucleic Acid Isolation and Purification Market Size
Global nucleic acid isolation and purification market size was valued at USD 7.21 billion in 2024 and is projected to reach USD 15.44 billion by 2032, growing with a CAGR of 10.6% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nucleic Acid Isolation and Purification Market Trends
“Advancement of Automation and High-Throughput Technologies”
As the demand for faster, more efficient, and scalable nucleic acid extraction methods rises, automated systems are becoming crucial in handling large volumes of samples. These automated solutions streamline laboratory workflows, reduce manual labor, and enhance reproducibility, making them highly valuable in genomics, clinical diagnostics, and biotechnology applications. High-throughput platforms allow simultaneous processing of numerous samples, which is vital for large-scale studies, including those related to precision medicine and next-generation sequencing. Additionally, these advancements improve consistency in results, reduce the risk of human error, and accelerate research timelines. Automation also supports the growing trend of personalized medicine, enabling more efficient extraction and analysis of genetic material for individualized treatment plans. The ability to perform high-quality nucleic acid purification at scale is driving the expansion of this trend globally.
Report Scope and Nucleic Acid Isolation and Purification Market Segmentation
|
Attributes
|
Nucleic Acid Isolation and Purification Key Market Insights
|
|
Segments Covered
|
|
|
Country Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands, Denmark, Poland, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Qatar, Egypt, Kuwait, Bahrain, Oman, Rest of Middle East and Africa
|
|
Key Market Players
|
Merck KGaA (Germany), Cutiva (Danaher Corporation) (U.S.), Meridian Bioscience, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Illumina Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN (Netherlands), Takara Bio Inc. (Japan), Promega Corporation (U.S.), MACHEREY-NAGEL GmbH & Co. KG (Germany), New England Biolabs (U.S.), Omega Bio-tek, Inc. (U.S.), Zymo Research Corporation (U.S.), Analytik Jena GmbH+Co. KG (Germany), MagGenome Technologies Pvt. Ltd. (India), AUTOGEN INC. (U.S.), Xi'an Tianlong Science and Technology Co., Ltd. (China), PCR Biosystems (UK), Sage Science, Inc. (U.S.), and ALS (Australia) among others
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Nucleic Acid Isolation and Purification Market Definition
The nucleic acid isolation and purification market refers to the sector focused on the extraction and purification of nucleic acids (DNA, RNA, and other genetic material) from biological samples for various applications, including molecular biology research, clinical diagnostics, forensic analysis, and biotechnology. This market encompasses a wide range of techniques and products such as reagent kits, automated systems, and laboratory equipment used to isolate and purify nucleic acids with high precision and efficiency. Key drivers include the growing demand for personalized medicine, advancements in genomics research, the increasing prevalence of genetic disorders, and the expansion of applications in areas like cancer research, infectious disease diagnostics, and genetic testing. The market is also influenced by technological innovations, such as Next-Generation Sequencing (NGS), which requires highly refined nucleic acid purification methods to ensure the accuracy and quality of sequencing results. The rise in research and clinical applications in emerging markets, along with the increasing number of biotechnology and pharmaceutical companies, contributes to the market’s growth.
Nucleic Acid Isolation and Purification Market Dynamics:
Drivers
- Increasing Prevalence of Genetic Disorders
The increasing prevalence of genetic disorders is a significant driver in the global nucleic acid isolation and purification market, as it fuels the demand for advanced diagnostic and therapeutic solutions essential for early detection, accurate diagnosis, and personalized treatment strategies. As genetic disorders, including conditions such as cystic fibrosis, Huntington’s disease, and various forms of cancer, continue to affect millions worldwide, the need for precise and reliable nucleic acid isolation techniques becomes paramount. These techniques are critical for extracting high-quality DNA and RNA from patient samples, which are subsequently used in a variety of molecular diagnostics, including Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and other genomic analyses that identify genetic mutations and biomarkers. The surge in genetic research and the push towards personalized medicine necessitate robust nucleic acid purification methods to support the development of targeted therapies and gene therapies, thereby enhancing patient outcomes. The rising incidence of genetic disorders drives investments in the biotechnology and pharmaceutical sectors, leading to the expansion of laboratories and research facilities that rely on efficient nucleic acid isolation technologies. Consequently, the interplay between the rising prevalence of genetic disorders and the advancement of molecular diagnostic technologies propels the growth of the nucleic acid isolation and purification market, driving innovation, expanding market reach, and fostering global collaborations to address the challenges posed by genetic diseases effectively.
For instance,
- In February 2024, according to an article, ‘Global distribution of β-thalassemia mutations: An update’, globally, approximately 60,000 newborns are born with the β-thalassemia major per year, with the majority living in developing countries and constituting about 1.5 % of the total population. It is the most common autosomal recessively inherited blood disorder. Hence, increasing cases of genetic disorders act as a driver in the growth of the market.
The rising occurrence of genetic disorders strongly drives the global demand for nucleic acid isolation and purification, as these methods are essential for accurate diagnostics, early detection, and personalized treatment approaches. High-quality DNA and RNA extraction is crucial for advanced molecular analyses like NGS and PCR, which identify genetic mutations and support targeted therapies. Also, progress in genomics and gene-editing techniques heighten the need for precise purification systems that maintain genetic material integrity, fostering innovation and international collaboration to address the growing burden of genetic conditions.
- Increasing Demand for Diagnostic Testing
The growing demand for diagnostic testing is a key driver in the global nucleic acid isolation and purification market, as more healthcare providers and researchers rely on these techniques to extract high-quality genetic material for a range of applications. Diagnostic testing for infectious diseases, cancer, genetic disorders, and other health conditions requires precise and rapid nucleic acid isolation to obtain DNA and RNA samples that enable accurate, reliable results. This demand is further fueled by the expansion of molecular diagnostics and advancements in technologies such as PCR, Next-Generation Sequencing (NGS), and CRISPR, all of which depend on purified nucleic acids for detecting pathogens, identifying mutations, and guiding personalized treatment decisions. Also, the rise in routine screening, preventive testing, and decentralized testing models such as point-of-care diagnostics has increased the volume of testing, thereby boosting the need for scalable and efficient nucleic acid isolation and purification solutions.
For instance,
- In March 2024, according to a news article published by Springer Nature, demand for diagnostic testing surges significantly with rising transmission rates and potential outbreak scenarios. High transmission settings, such as densely populated areas or environments with close-contact interactions, require frequent and rapid testing to manage virus spread effectively. As testing becomes central to early detection, contact tracing, and monitoring of infection rates, nucleic acid testing systems, particularly automated ones, are increasingly vital. The findings underscore that the demand for fast, accurate diagnostic testing will continue to grow, driven by the need for effective outbreak control and public health safety
The surge in diagnostic testing drives the nucleic acid isolation and purification market by creating a high demand for quality DNA and RNA extraction essential for accurate molecular diagnostics. With advancements in techniques like PCR and NGS and the rise in routine and point-of-care testing, the need for efficient, scalable purification methods continues to expand, supporting timely and precise disease detection and personalized care.
Opportunity
- Rise in Technological Advancements and Automation
Technological advancements and automation are driving significant growth opportunities in the global nucleic acid isolation and purification market by enhancing accuracy, speed, and scalability in genetic research and diagnostics. Innovations like fully automated extraction systems, high-throughput sequencing, and microfluidics reduce manual intervention, minimizing human error and improving consistency in sample processing. These advancements cater to the growing demand in genomics, proteomics, and personalized medicine by enabling labs to process larger sample volumes with precision and efficiency. Automation allows for integration with downstream analysis tools, creating seamless workflows that save time and reduce costs for laboratories. This enhanced throughput capability supports the expanding applications of nucleic acid-based diagnostics, especially in oncology, infectious diseases, and genetic disorder screening. As these technologies evolve, they also facilitate real-time monitoring and remote accessibility, which are particularly beneficial for decentralized and point-of-care testing, further broadening market growth potential. As automation becomes more accessible, it opens doors for more research institutions, clinical labs, and biotechnology firms to adopt sophisticated nucleic acid isolation and purification technologies, accelerating discovery and innovation across various fields.
For instance,
- In December 2023, according to the article published by Technology Networks, Thermo Fisher Scientific Inc., a global leader in scientific services, has launched the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument, along with the Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit. These products work together to enable the isolation and purification of viral and bacterial pathogens from respiratory samples. Designed for In Vitro Diagnostic (IVD) and In Vitro Diagnostic Regulation (IVD-R) compliance, these automated solutions provide laboratories with enhanced reliability for downstream testing results.
The rapid advancements in technology and automation are transforming the nucleic acid isolation and purification market by boosting accuracy, efficiency, and integration with downstream processes. These innovations enable labs to meet growing demand across genomics, diagnostics, and personalized medicine with higher throughput and reduced costs. As these technologies become more widely accessible, they expand research and diagnostic capabilities, driving broader adoption in labs and institutions worldwide ultimately accelerating progress across numerous scientific and medical fields.
Restraint/Challenge
- Risks Associated with Sample Contamination
The risk of sample contamination acts as a major restraint in the global nucleic acid isolation and purification market, as even slight contamination can compromise the integrity and accuracy of DNA or RNA samples, leading to unreliable results. Contaminated samples may interfere with downstream applications such as Next-Generation Sequencing (NGS) or PCR, affecting diagnostics, research outcomes, and therapeutic developments. This poses significant challenges for laboratories, particularly in high-throughput settings, as contamination can increase costs, time, and resources required for retesting and validation. As a result, maintaining sample purity becomes crucial, and the need for highly reliable and contamination-free isolation systems drives continuous innovation in the market.
For instance,
- In January 2023, according to an article published by Oxford Academic, laboratory contamination had severe and widespread negative impacts on both diagnostic testing and laboratory staff. These impacts extend far beyond an individual patient’s sample, possibly jeopardizing the integrity of a multitude of patient samples and instruments.
The risk of sample contamination hinders the nucleic acid isolation and purification market by compromising the accuracy and reliability of results, leading to increased costs and delays. This challenges laboratories to maintain high standards of purity, driving demand for more reliable and contamination-resistant purification systems. The persistent concern over contamination imposes an additional burden on laboratories in terms of operational protocols and resource allocation.
Nucleic Acid Isolation and Purification Market Scope
The nucleic acid isolation and purification market is segmented on the basis of product, method, type, application, sample type, end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Instruments
- Type
- Homogenizer
- Spectrophotometers
- Fluorometers
- Others
- Modality
- Benchtop
- Standalone
- Usability
- Automated
- Manual
- Type
- Kits
- DNA Isolation & Purification Kits
- Magnetic Bead-Based Kit
- Viral/Pathogen Nucleic Acid Isolation Kit
- Plant DNA Isolation Kit
- Cell-Free Total Nucleic Acid Kit
- Cell-Free DNA Isolation Kit
- Column-Based Kit
- Genomic DNA Purification Kit
- Viral RNA/DNA Purification Kit
- Plant DNA Purification Kit
- Microbiome DNA Purification Kit
- Others
- Reagent-Based Kit
- Magnetic Bead-Based Kit
- RNA Isolation & Purification Kits
- Magnetic Bead-Based Kit
- Viral/Pathogen Nucleic Acid Isolation Kit
- mRNA Purification Kit
- Plant RNA Isolation Kit
- Cell-Free Nucleic Acid Isolation Kit
- Others
- Column-Based Kit
- RNA Isolation Kit
- Mi RNA Isolation Kit
- Viral RNA/DNA Kit
- Reagent-Based Kit
- Magnetic Bead-Based Kit
- Viral Nucleic Acid Isolation kits
- Magnetic Bead-Based Kits
- Viral Spin-Column Kits
- Plasmid Purification Kit
- PCR and Gel kit
- Others
- DNA Isolation & Purification Kits
- Reagents
- DNA Isolation Reagent
- RNA Isolation Reagent
- Others
Method
- Magnetic Bead-Based Isolation and Purification
- Column -Based Isolation and Purification
- Reagent-Based Isolation and Purification
- Others
Type
- Next Generation Sequencing (NGS)
- Genomic DNA Isolation and Purification
- Total RNA Isolation and Purification
- PCR Clean-Up
- Plasmid DNA Isolation and Purification
- Messenger RNA Isolation and Purification
- Circulating Nucleic Acid Isolation and Purification
- MicroRNA Isolation and Purification
- Others
Application
- Diagnostics
- Instruments
- Kits
- Reagents
- Drug Discovery and Development
- Instruments
- Kits
- Reagents
- Personalized Medicine
- Instruments
- Kits
- Reagents
- Agriculture and Animal Research
- Instruments
- Kits
- Reagents
- Others
Sample Type
- FFPE Samples
- Blood Cells
- Bacteria, Yeast, and Plants
- Cell-Free Samples
- Cultured Cells
- Mammalian Cells
- Brain and Kidney Tissue
- Others
End User
- Hospitals and Diagnostic Centers
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Contract Development and manufacturing Organization (CDMO)
- Academic/Research Institutes
- Others
Nucleic Acid Isolation and Purification Market Regional Analysis
The market is analyzed and market size insights and trends are provided by product, method, type, application, sample type, end user, as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands, Denmark, Poland, Sweden, Norway, Finland, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Qatar, Egypt, Kuwait, Bahrain, Oman, rest of Middle East and Africa.
North America holds the largest share of the market, attributed to its advanced healthcare infrastructure, substantial investment in research and development, and high innovation levels. Europe follows closely, with a strong market presence driven by similar factors.
The Asia-Pacific region is expected to witness the fastest growth rate due to rapid advancements in healthcare infrastructure and increased investments in research and development across the region. Also, increasing prevalence of genetic disorders, increasing demand for diagnostic testing, rising investment in genomics research and increase in launch of diagnostic products are driving the adoption of global nucleic acid isolation and purification market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Nucleic Acid Isolation and Purification Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Nucleic Acid Isolation and Purification Market Leaders Operating in the Market Are:
- Merck KGaA (Germany)
- Cutiva (Danaher Corporation) (U.S.)
- Meridian Bioscience, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Illumina Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN (Netherlands)
- Takara Bio Inc. (Japan)
- Promega Corporation (U.S.)
- MACHEREY-NAGEL GmbH & Co. KG (Germany)
- New England Biolabs (U.S.)
- Omega Bio-tek, Inc. (U.S.)
- Zymo Research Corporation (U.S.)
- Analytik Jena GmbH+Co. KG (Germany)
- MagGenome Technologies Pvt. Ltd. (India)
- AUTOGEN INC. (U.S.)
- Xi'an Tianlong Science and Technology Co., Ltd. (China)
- PCR Biosystems (UK)
- Sage Science, Inc. (U.S.)
- ALS (Australia)
Latest Developments in Nucleic Acid Isolation and Purification Market
- In August 2024, Bio-Rad had launched the VeriCheck ddPCR Empty Full Capsid Kit, designed to enhance the development of safe and effective gene therapies. This high-precision kit enables accurate quantification of viral capsids, improving research and quality control in gene therapy applications
- In May 2024, Thermo, Fisher and BRIN have partnered to enhance research capabilities in Indonesia, focusing on advancing scientific innovation and collaboration in life sciences, biotechnology, and environmental studies for local researchers
- In September 2021, PerkinElmer, Inc. has successfully completed its acquisition of BioLegend for approximately USD 5.25 billion, marking its largest acquisition to date. This strategic move enhances PerkinElmer's life sciences portfolio in areas like cytometry and proteogenomics. Leaders from both companies anticipate collaborative innovation that will drive new therapeutic discoveries and advance scientific research
- In March 2025, Medtronic announced that it had been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2025 World's Most Ethical Companies opens a new window. This helped the organization develop a brand image among other leaders
- In April 2022, GE HealthCare. announced receiving the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2Anesthesia Delivery System. This increased the company's product portfolio and overall revenue
SKU-